RxDoctor Payments Data

Brittany Moore

Family · Fleetwood, PANPI 1619326667

Payments from drug & device makers

$5,497in general payments, 2019–2025

Across 268 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Ardelyx, Inc.$387
  • Takeda Pharmaceuticals U.S.A., Inc.$378
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$365
  • Johnson & Johnson$351
  • Madrigal Pharmaceuticals$293
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$701%
  • Food & beverage$5,42799%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,497 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$49,716
Medicare patients
360
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide161$110,450
CreonLipase/Protease/Amylase42$99,226
XifaxanRifaximin14$61,603
TrulancePlecanatide13$8,221
Dexlansoprazole DrDexlansoprazole19$4,044
Omeprazole373$3,785
Pantoprazole Sodium233$3,214
Lubiprostone43$2,936
Esomeprazole Magnesium34$2,794
Famotidine183$1,948
Sucralfate48$1,626
Dicyclomine Hcl54$955
Colestipol Hcl23$940
Lansoprazole16$425
Ondansetron Hcl31$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,743$209,676203 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$365$69,82527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Fleetwood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →